See how top analysts and institutions rate XPEV — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| BNP Paribas Exane | Initiated | Neutral | $19 | 2025-08-18 |
| Goldman | Upgrade | Neutral → Buy | $16.40 → $24 | 2025-06-17 |
| Macquarie | Upgrade | Neutral → Outperform | 2025-05-21 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 6 | 15 | 6 | 0 | 1 |
| October 2025 | 6 | 15 | 6 | 0 | 1 |
| September 2025 | 6 | 15 | 6 | 0 | 1 |
| August 2025 | 6 | 15 | 6 | 0 | 1 |
The majority of institutional investors have issued a "Buy" rating for XPEV, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
